$ENSC News

Ensysce Biosciences Expands Global Investor and Strategic Outreach at Family Office Summit, Dubai

Cantor Fitzgerald Initiates Coverage On Ensysce Biosciences with Overweight Rating, Announces Price Target of $2

Ensysce Biosciences Phase 2 Protocol for CY200 - A Neuroplastigen for the Treatment of CRPS - Submitted to the UK MHRA

Ensysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug Regulation

Ensysce Biosciences' Professor Richard Langford Selected to Speak at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs

Ensysce Biosciences Completes Final Phase of PF614-MPAR-102 Clinical Study

Ensysce Biosciences Completes Enrollment In Final Stage Of PF614-MPAR-102 Clinical Study

Ensysce Biosciences to Showcase "A New Era in Pain Therapeutics" at PAINWeek 2026 Symposium

Ensysce Biosciences, Inc. (ENSC) Discusses Acquisition of Cy Biopharma and Private Placement Financing Prepared Remarks Transcript

ENSC Sets Itself Up Nicely for Critical Stage

Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Ensysce Biosciences Q2 EPS $(0.20) Beats $(0.50) Estimate, Sales $1.164M Beat $1.000M Estimate

Ensysce Biosciences Completes Cy Biopharma Acquisition and Secures Up to $77 Million Private Financing

Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing

ENSC Makes Bold Move that Bolsters Pipeline and Finances

Ensysce Biosciences Completes Acquisition Of Cy Biopharma, Secures $17.1M Cash Financing And $21.5M Series C Preferred Stock Private Placement With Potential $38.6M Follow-On Tranche To Fund CY200 Development Through 2028

Ensysce Biosciences Has Received A Notice Of Allowance For A U.S. Patent Titled "COMPOSITIONS COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF".

Ensysce Biosciences Receives Final $5.3 Million NIDA Funding Installment for PF614-MPAR Development

Ensysce Biosciences Awarded $5.3 Million Installment in NIDA Funding Completing Multi-Year $15 Million Federal Grant

ENSC Receives Vital Funding for Drive to Commercialization